Você pesquisou por y - Revista Brasileira de Ginecologia e Obstetrícia
You searched for:"Thelma Larocca Skare"
We found (6) results for your search.Summary
Rev Bras Ginecol Obstet. 2011;33(7):132-136
DOI 10.1590/S0100-72032011000700003
PURPOSE: To study if rheumatoid arthritis (RA) is influenced by age at menarche, number of pregnancies and reproductive life span. METHODS: This was a cross-sectional and retrospective study of medical records of 247 RA patients. We collected data on menarche, menopause, number of pregnancies, autoantibodies, serositis, rheumatoid nodules, and functional index of Steinbrocker. Association studies were done using the Student t and Mann-Whitney tests and correlation was determined by the Pearsonand Spearman tests. The level of significance adopted was 5%. RESULTS: The mean age at diagnosis of RA was 43.2±14.1 years, the median age at menarche was 13 years and the median number of pregnancies was 3. Rheumatoid factor was present in 63.9% of the patients, 20% had antinuclear factor, 8.8% rheumatoid nodules, 2.8% had pleural effusion, and 2.4% had pericarditis. The Steinbrocker functional index showed that 45.6% had a score of 1, 40.8% a score of 2, 3 score of 9.1, and 4.3% a score of 4. We found an inverse correlation between the number of pregnancies and age at onset of RA (p CONCLUSION: A precocious menarche and brief reproductive life indicate a poor prognosis regarding pleurisy. A larger number of pregnancies and late menopause show a protective effect, delaying the onset of the disease.
Summary
Rev Bras Ginecol Obstet. 2011;33(7):132-136
DOI 10.1590/S0100-72032011000700003
PURPOSE: To study if rheumatoid arthritis (RA) is influenced by age at menarche, number of pregnancies and reproductive life span. METHODS: This was a cross-sectional and retrospective study of medical records of 247 RA patients. We collected data on menarche, menopause, number of pregnancies, autoantibodies, serositis, rheumatoid nodules, and functional index of Steinbrocker. Association studies were done using the Student t and Mann-Whitney tests and correlation was determined by the Pearsonand Spearman tests. The level of significance adopted was 5%. RESULTS: The mean age at diagnosis of RA was 43.2±14.1 years, the median age at menarche was 13 years and the median number of pregnancies was 3. Rheumatoid factor was present in 63.9% of the patients, 20% had antinuclear factor, 8.8% rheumatoid nodules, 2.8% had pleural effusion, and 2.4% had pericarditis. The Steinbrocker functional index showed that 45.6% had a score of 1, 40.8% a score of 2, 3 score of 9.1, and 4.3% a score of 4. We found an inverse correlation between the number of pregnancies and age at onset of RA (p CONCLUSION: A precocious menarche and brief reproductive life indicate a poor prognosis regarding pleurisy. A larger number of pregnancies and late menopause show a protective effect, delaying the onset of the disease.
Summary
Rev Bras Ginecol Obstet. 2012;34(4):170-174
DOI 10.1590/S0100-72032012000400006
PURPOSE: To assess the prevalence of lacrimal dysfunction during pregnancy comparing it to non-pregnant women and to correlate these findings with obstetric history. METHODS: We interviewed 150 pregnant and 150 non-pregnant women for symptoms of dry eyes and obstetric history. Both groups underwent Schirmer I testing and responded to a questionnaire on dry eye symptoms. Patients with collagen diseases, medications associated with dryness of mucous membranes, hepatitis C infection and AIDS, previous intraocular inflammation and eye surgery were excluded. Data were analyzed by the Χ2 and Fisher tests when the data were nominal and by the Student´s t-test and Mann-Whitney test when numerical. The level of significance was set at 5%. RESULTS: The two groups did not differ in symptoms of lacrimal dysfunction. The results of Schirmer's test were equal in both groups for the right eye (p=0.3) and left eye (p=0.3). However, pregnant women had a higher prevalence of at least one dry eye (p=0.004). The occurrence of dry eye in both groups (patients and controls) was associated with a greater number of full-term pregnancies/patient (p=0.04) but not with pregnancy time (p=0.5) or number of abortions (p=0.9). CONCLUSIONS: Pregnant women suffer more from lacrimal dysfunction than non pregnant women; in both groups the prevalence of tear dysfunction is more elevated in women with higher parity.
Summary
Rev Bras Ginecol Obstet. 2012;34(4):170-174
DOI 10.1590/S0100-72032012000400006
PURPOSE: To assess the prevalence of lacrimal dysfunction during pregnancy comparing it to non-pregnant women and to correlate these findings with obstetric history. METHODS: We interviewed 150 pregnant and 150 non-pregnant women for symptoms of dry eyes and obstetric history. Both groups underwent Schirmer I testing and responded to a questionnaire on dry eye symptoms. Patients with collagen diseases, medications associated with dryness of mucous membranes, hepatitis C infection and AIDS, previous intraocular inflammation and eye surgery were excluded. Data were analyzed by the Χ2 and Fisher tests when the data were nominal and by the Student´s t-test and Mann-Whitney test when numerical. The level of significance was set at 5%. RESULTS: The two groups did not differ in symptoms of lacrimal dysfunction. The results of Schirmer's test were equal in both groups for the right eye (p=0.3) and left eye (p=0.3). However, pregnant women had a higher prevalence of at least one dry eye (p=0.004). The occurrence of dry eye in both groups (patients and controls) was associated with a greater number of full-term pregnancies/patient (p=0.04) but not with pregnancy time (p=0.5) or number of abortions (p=0.9). CONCLUSIONS: Pregnant women suffer more from lacrimal dysfunction than non pregnant women; in both groups the prevalence of tear dysfunction is more elevated in women with higher parity.
Summary
Rev Bras Ginecol Obstet. 2015;37(6):272-277
DOI 10.1590/SO100-720320150005301
To evaluate the ovarian response after cyclophosphamide use (CPM) in patients
with systemic lupus erythematosus (SLE) and to correlate the age and cumulative
dose findings with changes in menstrual cycle and/or progression to ovarian
failure (OF).
This was a cross-sectional, retrospective study of 50 patients with a diagnosis
of SLE who used CFM with a clinical follow-up of at least 1 year. Included were
patients aged 12-40 years, who had undergone chemotherapy for SLE control and who
had regular menstrual cycles before the beginning of CPM treatment. Patients who
discontinued follow-up, who were followed up for less than one year or who had
irregular/absent menses before the beginning of CPM treatment were excluded. All
women studied were submitted to an interview and a questionnaire containing
questions about the pattern of the menstrual cycle before and after therapy, and
about the gestational periods and contraception. We asked if the patients had been
instructed about the side effects and consequences of CFM. Statistical analysis
was performed using the Student t-test and the Mann Whitney, χ2 and
nonparametric Kolmogorov-Smirnov tests.
The mean age of the patients included in the study was 30.8 years and the mean
age at the time of use of CPM was 25.3 years. After CFM, 24% of patients stopped
menstruating, 28% returned to regular cycles and 48% continued to have irregular
cycles. It was found that the patients who developed OF had longer disease
duration (12.3 years) than those who did not develop it (8.9 years). Thirteen
patients became spontaneously pregnant after CFM; however, 66% progressed to
abortion. The mean age of the patients who used CFM and developed OF was 28.1
years. Amenorrhea occurred in 50% of those aged 31-40 years, in 22.2% of those
aged 21-30 years and in 7.7% of those aged 12-20 years. Our study showed no
statistical correlation between cumulative dose and OF, although cumulative doses
greater than 11grams tended to promote some type of menstrual irregularity.
SLE disease duration, age at the time of treatment and the highest cumulative
doses are important predictors of OF after therapy with CFM. Pregnancy in lupus
patients is more likely to evolve with abortion after the use of chemotherapy. It
was seen that a small proportion of patients were aware of all the implications of
the drug. Therefore, additional studies should be conducted for further knowledge
and awareness of the importance of contraception and the preservation of ovarian
tissue on the part of the medical community.
Summary
Rev Bras Ginecol Obstet. 2015;37(6):272-277
DOI 10.1590/SO100-720320150005301
To evaluate the ovarian response after cyclophosphamide use (CPM) in patients
with systemic lupus erythematosus (SLE) and to correlate the age and cumulative
dose findings with changes in menstrual cycle and/or progression to ovarian
failure (OF).
This was a cross-sectional, retrospective study of 50 patients with a diagnosis
of SLE who used CFM with a clinical follow-up of at least 1 year. Included were
patients aged 12-40 years, who had undergone chemotherapy for SLE control and who
had regular menstrual cycles before the beginning of CPM treatment. Patients who
discontinued follow-up, who were followed up for less than one year or who had
irregular/absent menses before the beginning of CPM treatment were excluded. All
women studied were submitted to an interview and a questionnaire containing
questions about the pattern of the menstrual cycle before and after therapy, and
about the gestational periods and contraception. We asked if the patients had been
instructed about the side effects and consequences of CFM. Statistical analysis
was performed using the Student t-test and the Mann Whitney, χ2 and
nonparametric Kolmogorov-Smirnov tests.
The mean age of the patients included in the study was 30.8 years and the mean
age at the time of use of CPM was 25.3 years. After CFM, 24% of patients stopped
menstruating, 28% returned to regular cycles and 48% continued to have irregular
cycles. It was found that the patients who developed OF had longer disease
duration (12.3 years) than those who did not develop it (8.9 years). Thirteen
patients became spontaneously pregnant after CFM; however, 66% progressed to
abortion. The mean age of the patients who used CFM and developed OF was 28.1
years. Amenorrhea occurred in 50% of those aged 31-40 years, in 22.2% of those
aged 21-30 years and in 7.7% of those aged 12-20 years. Our study showed no
statistical correlation between cumulative dose and OF, although cumulative doses
greater than 11grams tended to promote some type of menstrual irregularity.
SLE disease duration, age at the time of treatment and the highest cumulative
doses are important predictors of OF after therapy with CFM. Pregnancy in lupus
patients is more likely to evolve with abortion after the use of chemotherapy. It
was seen that a small proportion of patients were aware of all the implications of
the drug. Therefore, additional studies should be conducted for further knowledge
and awareness of the importance of contraception and the preservation of ovarian
tissue on the part of the medical community.
Summary
Rev Bras Ginecol Obstet. 2021;43(5):357-361
To study a sample of rheumatoid arthritis (RA) patients for their gynecological/obstetric history and compare them to controls to determine their influences on number of pregnancies, menarche, menopause and reproductive years following RA onset.
This is a cross-sectional study of 122 RA patients and 126 controls. Patients and controls were questioned about age of menarche, age of menopause, number of pregnancies and abortions. Reproductive years were calculated as the difference between age at menopause and age at menarche. For comparison, we used the Mann-Whitney, unpaired t, chi-squared, and Spearman tests. The adopted significance was 5%.
In the RA patients with disease beginning in the postmenopausal years, the period of reproductive years (age at menopause - age of menarche) showed a positive correlation with age at disease onset (rho=0.46; 95% confidence interval [CI]=0.20- 0.55 with p=0.0008). The number of pregnancies was higher in patients with postmenopausal disease onset when compared with those with premenopausal disease onset (median of 3 with interquartile range [IQR]=2-4 versus median of 2 with IQR=1-3; p=0.009), and RA patients had more pregnancies than controls (p=0.0002).
The present study shows that, in our population, the duration of reproductive years and the number of pregnancies are linked to the onset of RA.
Summary
Rev Bras Ginecol Obstet. 2021;43(5):357-361
To study a sample of rheumatoid arthritis (RA) patients for their gynecological/obstetric history and compare them to controls to determine their influences on number of pregnancies, menarche, menopause and reproductive years following RA onset.
This is a cross-sectional study of 122 RA patients and 126 controls. Patients and controls were questioned about age of menarche, age of menopause, number of pregnancies and abortions. Reproductive years were calculated as the difference between age at menopause and age at menarche. For comparison, we used the Mann-Whitney, unpaired t, chi-squared, and Spearman tests. The adopted significance was 5%.
In the RA patients with disease beginning in the postmenopausal years, the period of reproductive years (age at menopause - age of menarche) showed a positive correlation with age at disease onset (rho=0.46; 95% confidence interval [CI]=0.20- 0.55 with p=0.0008). The number of pregnancies was higher in patients with postmenopausal disease onset when compared with those with premenopausal disease onset (median of 3 with interquartile range [IQR]=2-4 versus median of 2 with IQR=1-3; p=0.009), and RA patients had more pregnancies than controls (p=0.0002).
The present study shows that, in our population, the duration of reproductive years and the number of pregnancies are linked to the onset of RA.
Summary
Rev Bras Ginecol Obstet. 2014;36(8):367-371
DOI 10.1590/SO100-720320140005052
To study the incidence of tumors in a Brazilian sample of women with systemic lupus erythematosus.
This is a retrospective study of 395 medical charts from women with systemic lupus erythematosus diagnosed by the presence of at least 4 of the American College of Rheumatology classification criteria for the diagnosis of this disease and followed for the last 10 years in a rheumatology outpatient clinic. Demographic data (age and ethnicity of patients), data on disease duration, use of immunomodulators and on the presence of neoplasms were listed. Results are presented in frequency and contingency tables. The incidence rate of malignancies in women with lupus was compared with that of the general population for the same demographic region for the past ten years, using data published by the Brazilian National Cancer Institute (INCA). Association studies were carried out by the Fisher and χ tests, when the data were nominal, and by Mann-Whitney test, when numeric. The level of significance was set at 5%.
Twenty-two cases of malignant tumors were identified during these 10 years of follow-up (22 cases/395 or 5.5% of the sample), being the most common those of the uterine cervix (10 cases/395 or 2.5% of the sample) and breast cancer (9 cases/395 or 2.2% of the sample). The presence of tumors was associated with disease duration (p=0.006) and was not influenced by treatment with methotrexate (p=0.1), azathioprine (p=0.9), cyclophosphamide (p=0.6) and glucocorticoids (p=0.3). Breast and uterine cervix tumors were more common in systemic lupus erythematosus women than in the general population (p<0.0001 for both).
A high prevalence of malignant tumors was found in this sample, with tumors being more common in patients with longer disease duration. The most frequent tumors affected the breast and uterus at a higher incidence than in the general population. The presence of tumors was not influenced by the use of glucocorticoids or immunosuppressors.
Summary
Rev Bras Ginecol Obstet. 2014;36(8):367-371
DOI 10.1590/SO100-720320140005052
To study the incidence of tumors in a Brazilian sample of women with systemic lupus erythematosus.
This is a retrospective study of 395 medical charts from women with systemic lupus erythematosus diagnosed by the presence of at least 4 of the American College of Rheumatology classification criteria for the diagnosis of this disease and followed for the last 10 years in a rheumatology outpatient clinic. Demographic data (age and ethnicity of patients), data on disease duration, use of immunomodulators and on the presence of neoplasms were listed. Results are presented in frequency and contingency tables. The incidence rate of malignancies in women with lupus was compared with that of the general population for the same demographic region for the past ten years, using data published by the Brazilian National Cancer Institute (INCA). Association studies were carried out by the Fisher and χ tests, when the data were nominal, and by Mann-Whitney test, when numeric. The level of significance was set at 5%.
Twenty-two cases of malignant tumors were identified during these 10 years of follow-up (22 cases/395 or 5.5% of the sample), being the most common those of the uterine cervix (10 cases/395 or 2.5% of the sample) and breast cancer (9 cases/395 or 2.2% of the sample). The presence of tumors was associated with disease duration (p=0.006) and was not influenced by treatment with methotrexate (p=0.1), azathioprine (p=0.9), cyclophosphamide (p=0.6) and glucocorticoids (p=0.3). Breast and uterine cervix tumors were more common in systemic lupus erythematosus women than in the general population (p<0.0001 for both).
A high prevalence of malignant tumors was found in this sample, with tumors being more common in patients with longer disease duration. The most frequent tumors affected the breast and uterus at a higher incidence than in the general population. The presence of tumors was not influenced by the use of glucocorticoids or immunosuppressors.
Summary
Rev Bras Ginecol Obstet. 2005;27(10):594-598
DOI 10.1590/S0100-72032005001000005
PURPOSE: to verify if there is any difference in the number of miscarriages and newborns with low weight in patients with scleroderma (SSc) when compared with women without the disease, between the two clinical variants of the disease and when the expression of SSc occurred before or after the gestation. METHODS: twenty-six patients were analyzed regarding the number of pregnancies, miscarriages, sex, and birth weight of the children, studying the clinical variant of the disease and the temporal relationship between diagnosis and gestation. The patients had not used either medications that could interfere in gestation or had any other disease that could do it. For control, twenty-six healthy women, without diseases that might alter the gestation, of the same ages and socioeconomic status were studied. For the statistical analysis study, tables of frequency, tables of contingency, and Fisher, chi2 and Mann-Whitney tests were used. Statistical significance was considered when p<0.05. RESULTS: among the patients with SSc, there were 96 gestations with 13.5% (n=13) of miscarriages. In the control group, there were 94 gestations with 9.6% (n=9) of miscarriages. There were no differences in the number of newborns with low weight between the two groups (cases, n=8 and controls, n=6, with p=0.54), nor in the number of miscarriages (p=0.46). However, the number of newborn babies with low weight was significantly higher among the cases with the diffuse disease (diffuse form, n=4 and limited, n=4, with p=0.04) and among patients that became pregnant after the diagnosis of SSc (37.5% in women known to be sick and 6.7% in women who became pregnant before getting ill, with p=0.03). The number of male newborns was higher in the women with SSc (p=0.002). CONCLUSIONS: the women with SSc showed a higher number of low-weight newborns in the group with diffuse disease and when pregnancy occurred after the clinical diagnosis of the disease.
Summary
Rev Bras Ginecol Obstet. 2005;27(10):594-598
DOI 10.1590/S0100-72032005001000005
PURPOSE: to verify if there is any difference in the number of miscarriages and newborns with low weight in patients with scleroderma (SSc) when compared with women without the disease, between the two clinical variants of the disease and when the expression of SSc occurred before or after the gestation. METHODS: twenty-six patients were analyzed regarding the number of pregnancies, miscarriages, sex, and birth weight of the children, studying the clinical variant of the disease and the temporal relationship between diagnosis and gestation. The patients had not used either medications that could interfere in gestation or had any other disease that could do it. For control, twenty-six healthy women, without diseases that might alter the gestation, of the same ages and socioeconomic status were studied. For the statistical analysis study, tables of frequency, tables of contingency, and Fisher, chi2 and Mann-Whitney tests were used. Statistical significance was considered when p<0.05. RESULTS: among the patients with SSc, there were 96 gestations with 13.5% (n=13) of miscarriages. In the control group, there were 94 gestations with 9.6% (n=9) of miscarriages. There were no differences in the number of newborns with low weight between the two groups (cases, n=8 and controls, n=6, with p=0.54), nor in the number of miscarriages (p=0.46). However, the number of newborn babies with low weight was significantly higher among the cases with the diffuse disease (diffuse form, n=4 and limited, n=4, with p=0.04) and among patients that became pregnant after the diagnosis of SSc (37.5% in women known to be sick and 6.7% in women who became pregnant before getting ill, with p=0.03). The number of male newborns was higher in the women with SSc (p=0.002). CONCLUSIONS: the women with SSc showed a higher number of low-weight newborns in the group with diffuse disease and when pregnancy occurred after the clinical diagnosis of the disease.
